Use of alpha-adrenoceptor antagonist dihydroergotoxin in experimental anticoagulant and fibrinolytic therapy.
The thrombolytic action of commercial plasmin-Fibrinolysin, heparin and complex Fibrinolysin-heparin in thecom bination with the alpha-adrenoceptor agent DET was studied in rats. The induction of venous thrombosis is accompanied by the manifestations of disseminated intravascular coagulation (DIC). The most efficient thrombolytic action in the hypercoagulemic stage of DIC had the complex Fibrinolysin-heparin in the combination with DET. The alpha-adrenoceptor antagonist blocked the compensatory reaction on plasmin excess, liberated vascular plasminogen activator and thus increased and prolonged thrombo- and fibrinolytic effects of this complex. Administration of this complex in the combination with DET resulted in a steady hypocoagulation and hyperfibrinolysis in blood stream.
Kalishevskaya
T M
TM
Laboratory of Blood Coagulation, Biological Faculty, Moscow State University, USSR.
Golubeva
M G
MG
Bashkov
G V
GV
D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use*; D004088:Dihydroergotoxine / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005341:Fibrinolysin / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D008297:Male; D051381:Rats; D013918:Thrombin Time; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy; D000979:alpha-2-Antiplasmin / Q000378:metabolism
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D000979:alpha-2-Antiplasmin; D004088:Dihydroergotoxine; D006493:Heparin; D005341:Fibrinolysin